Savvy Advisors Inc. significantly reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 83.5% in the third quarter of last year, selling 38,347 shares. This comes as Amgen reported strong Q3 results, beating EPS and revenue estimates, setting favorable FY2026 guidance, and increasing its quarterly dividend. Analysts maintain a “Moderate Buy” rating for Amgen with a consensus target price of $354.04.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Amgen Inc. $AMGN Shares Sold by Savvy Advisors Inc.
Savvy Advisors Inc. significantly reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 83.5% in the third quarter of last year, selling 38,347 shares. This comes as Amgen reported strong Q3 results, beating EPS and revenue estimates, setting favorable FY2026 guidance, and increasing its quarterly dividend. Analysts maintain a “Moderate Buy” rating for Amgen with a consensus target price of $354.04.